CD Genomics
Disease Panel

The Reasons for Choosing Our Cancer Panels

About CD Genomics' Disease Panels

Using cutting-edge techniques such as next-generation sequencing and microarray technologies, CD Genomics can provide comprehensive genomic services to support many industries, institutes, and companies. Based on rich experience in targeted sequencing, CD Genomics has developed a Disease Panel platform for targeted sequencing of disease-related genes to help researchers with cancer diagnostics and analysis, pathogen detection, and pharmacogenomics testing. The Disease Panel provides one-stop solutions (including both services and reagents) for the study of a wide range of diseases, including cancer, inherited disease, and infection by using NGS panels or non-NGS panels, which facilitate numerous applications such as disease research, biomarker discovery, and targeted drug development.

The Newly Launched Cancer Panels

CD Genomics' cancer panels are predesigned panels for targeted sequencing of genes and mutations associated with multiple cancer diseases. CD Genomics utilizes targeted NGS sequencing technology to provide more efficient and accurate targeting of specific genes or mutations, and even to detect low-frequency variations in cancer-associated genes. Targeted NGS sequencing facilitates sequencing of a large number of genes and samples in a single and cost-effective assay. CD Genomics provides a variety of cancer panels for your cancer-related research.

Cancer Panels can be used to detect more than 700 cancer-related genes, which cover both exons and coding sequences and ensures large-scale screening and identification efficiently and comprehensively. The panels include the broad-spectrum pan-cancer panel that covers more than 500 genes in a single panel and cancer-specific panels including hereditary cancer, cancer hotspot panel, lung cancer panel, breast cancer panel, ovarian cancer panel, thyroid carcinoma panel, esophageal cancer panel, glioma gene panel, and colorectal cancer panel.



Cancer Panel Workflow & One-Stop Services

We take Illumina PE150 amplicon sequencing-based strategy and offer predesigned NGS panels, which include a designed library of targeted sequencing, as well as a custom panel that allows customers to select genes of interest to design their own sequencing panels. CD Genomics provides an accurate and cost-effective cancer panel sequencing and bioinformatics analysis. Our team of professional experts executes quality management and strictly follows every procedure to ensure confident and unbiased results.



Highlights

- Target-enrichment sequencing by Illumina provides extremely high depth (average depth > 1000x) with low cost.
- High coverage uniformity ensures the efficient sequencing data.
- SNVs, indels, and even low frequency variations can be detected.
- Strict quality control throughout the pipeline workflow to ensure the accuracy and repeatability of the sequencing.
- Fast turnaround time.

CD Genomics is an innovative sequencing and genotyping company. Our Disease Panel platform provides a series of proprietary, ultra-high multiplexed NGS target enrichment technology that integrates the company's advanced panel design. The cancer panels are designed to address the practical needs of cancer-related studies. These panels are featured an innovative background cleaning technique that allows plenty of amplicons to be multiplexed in a single reaction pool, allowing a large number of cancer-related genes to be detected in a single assay. They can be designed as ready-to-use panels or as customized assays.

CD Genomics is dedicated to providing the highest level of sequencing services. With various solution options and experienced scientists, we offer the most suitable strategies according to your sample and research purpose. To find more about Cancer Panels, please feel free to contact us.

Contact CD Genomics for more inspiration and service content.

CD Genomics
Disease Panel